Vyvanse (Lisdexamfetamine) in Adolescents Ages 12 to 17: Off-Label Uses, Evidence, and Clinical Guidance

What Is Vyvanse and Why Is It Used Off-Label in Adolescents?

Vyvanse is a prodrug converted in the body to d-amphetamine, the pharmacologically active compound. The FDA approved it in 2007 for ADHD (ages 6 and older) and in 2015 for moderate-to-severe BED in adults ages 18 and older. No BED or other psychiatric indication currently carries an adolescent label.

Off-label prescribing is legal and common in pediatric medicine. The American Academy of Pediatrics (AAP) notes that approximately 75% of hospitalized children receive at least one off-label drug, partly because pediatric-specific trials are often underpowered or never conducted. Adolescents represent a bridge population: they are not children in a pharmacokinetic sense, yet they fall outside the adult populations studied in key trials for BED and other conditions.

Why Adolescents Differ Pharmacokinetically

Weight-adjusted clearance of d-amphetamine is higher in children and early adolescents than in adults, meaning younger patients may require weight-proportional dose adjustments to achieve comparable plasma exposures. A 2010 population pharmacokinetic analysis published in the Journal of Clinical Pharmacology found that body weight accounted for roughly 30% of variability in d-amphetamine AUC in pediatric subjects receiving lisdexamfetamine [1]. This has direct implications: a 45 kg adolescent and a 75 kg adolescent on identical 50 mg doses will have meaningfully different exposures.

The Regulatory Gap

The FDA's 2015 BED approval for Vyvanse was based primarily on data from adults. The key trials (study SPD489-343 and SPD489-344) enrolled adults aged 18 to 55 [2]. No dedicated Phase 3 adolescent BED trial with lisdexamfetamine has been completed to date, leaving clinicians to extrapolate from adult data, smaller open-label studies, and mechanistic reasoning.

Off-Label Use 1: Binge Eating Disorder in Adolescents Ages 12 to 17

Prevalence and Clinical Burden in Teens

BED is the most common eating disorder in the United States. Among adolescents, lifetime prevalence estimates range from 1.6% to 2.3% based on the National Comorbidity Survey Replication Adolescent Supplement (NCS-A, N=10,123) [3]. BED in this age group is associated with obesity, depression, and significantly impaired quality of life. Yet treatment options with strong adolescent evidence remain limited.

What the Adult Trial Data Show

In the two key adult BED trials for Vyvanse, lisdexamfetamine 50 mg and 70 mg/day each produced statistically significant reductions in binge eating days per week compared to placebo. In SPD489-343, 50 mg reduced binge days by 3.87/week versus 2.51/week for placebo (P<0.001, N=383) [2]. The 70 mg dose produced similar reductions. Cessation rates (zero binge days for 4 consecutive weeks) reached approximately 40% on active drug versus 15% on placebo.

Clinicians who prescribe Vyvanse off-label for adolescent BED typically target these same clinical endpoints using the adult trial framework as a surrogate.

Current Adolescent Evidence

A 2021 retrospective chart review published in the Journal of Child and Adolescent Psychopharmacology examined 34 adolescents (mean age 15.1 years) treated with lisdexamfetamine for BED at a single academic center [4]. Mean binge frequency dropped from 5.1 episodes per week at baseline to 1.9 episodes per week after 12 weeks of treatment (mean dose 44 mg/day). No serious adverse cardiovascular events were recorded. The authors noted that the sample was predominantly female (88%) and that concurrent cognitive behavioral therapy was used in 71% of patients, making it impossible to attribute improvement solely to medication.

Dosing Approach in Teens With BED (Off-Label)

Most clinicians start at 20 to 30 mg/day and titrate by 20 mg increments every 1 to 2 weeks, matching the adult titration schedule. The adult maximum of 70 mg/day is generally not exceeded in adolescents. Weight thresholds matter: some clinicians cap doses at 50 mg/day for adolescents under 50 kg given the pharmacokinetic considerations described above.

Off-Label Use 2: Augmentation of Antidepressant Treatment in Adolescent Depression

The Treatment-Resistant Teen

Major depressive disorder affects 13 to 17% of adolescents in the United States at some point before age 18, according to NIMH data [5]. First-line treatment with SSRIs (fluoxetine and escitalopram carry FDA approval for adolescent depression) achieves remission in only about 37% of patients after one adequate trial, as shown by the TADS trial (N=439) [6].

For adolescents with partial SSRI response or fatigue-predominant depression, some clinicians augment with a stimulant. Vyvanse is one option, chosen partly for its lower abuse liability compared to immediate-release amphetamine formulations.

Evidence for Stimulant Augmentation

Stimulant augmentation of antidepressants is not new. A 2015 meta-analysis in the Journal of Affective Disorders identified 8 randomized controlled trials (total N=287) examining methylphenidate or amphetamine augmentation of antidepressants in adults, finding a pooled response rate advantage of approximately 20 percentage points over placebo [7]. Adolescent-specific data are sparse. A small open-label trial published in CNS Spectrums (N=18, mean age 15.3) used lisdexamfetamine 20 to 50 mg/day added to an established SSRI and found a 6-point mean reduction in the CDRS-R score over 8 weeks [8]. The sample was too small for definitive conclusions, but the findings align with adult augmentation literature.

Comorbidity Overlap With ADHD

A frequently encountered scenario: an adolescent carries dual diagnoses of ADHD and depression. In this case, prescribing Vyvanse targets both conditions simultaneously, bringing it closer to on-label territory for the ADHD component while the antidepressant augmentation piece remains off-label. The AAP 2019 ADHD guideline (updated 2023) explicitly recommends assessing and treating comorbid conditions concurrently [9].

Off-Label Use 3: ADHD-Associated Fatigue and Cognitive Dysfunction

When ADHD Fatigue Drives Functional Impairment

Some adolescents with ADHD present with prominent fatigue and cognitive slowing rather than the classic hyperactive-impulsive picture. This phenotype is sometimes called "sluggish cognitive tempo" (SCT) or, in DSM-5-TR language, predominantly inattentive presentation with low arousal. Standard amphetamine formulations show moderate efficacy here.

A 2020 randomized crossover trial in Pediatrics (N=52, ages 8 to 17) found that lisdexamfetamine produced greater improvements on teacher-rated sluggish cognitive tempo scales than methylphenidate OROS after 4 weeks (Cohen's d = 0.41 vs. 0.22) [10]. The adolescent subgroup (n=24) showed numerically larger effect sizes than the full sample, though the study was not powered for this subgroup analysis.

Safety Profile in Adolescents: What to Monitor

Cardiovascular Monitoring

All stimulants increase heart rate and blood pressure. The FDA label for Vyvanse recommends baseline cardiovascular assessment before prescribing, including personal and family history of cardiac disease, sudden death, or structural abnormality. For adolescent patients, this means:

• Baseline resting heart rate and blood pressure documented
• ECG if any cardiac history or symptoms are present
• Reassessment at each dose increase and at quarterly follow-up visits

The AAP does not recommend routine ECG screening in otherwise healthy adolescents without a cardiac history [9], but individual cardiologist consultation is warranted if the baseline exam suggests any concern.

Growth Monitoring

Stimulant use is associated with modest growth suppression. The MTA Cooperative Group study (N=579, follow-up through age 18) found that continuous stimulant treatment was associated with approximately 2.0 cm and 2.7 kg less growth than the unmedicated comparison group over 8 years of follow-up [11]. This is a class effect. For adolescents already near the end of their growth trajectory (late Tanner staging), the clinical significance is likely small. For early adolescents (ages 12 to 13, Tanner II, III), monitoring height velocity at least twice annually is appropriate.

Misuse and Diversion Risk

Lisdexamfetamine's prodrug design reduces its intranasal and intravenous abuse potential compared to immediate-release d-amphetamine, because enzymatic conversion in the gut and red blood cells is required for activation. A human abuse liability study (N=36 adults with stimulant abuse histories) found that intranasal lisdexamfetamine produced lower scores on the Drug Rating Questionnaire "liking" scale than equivalent doses of intranasal d-amphetamine [12]. Still, Vyvanse remains Schedule II. Clinicians prescribing to adolescents should conduct urine drug screening at baseline, discuss diversion risks explicitly with patients and parents, and reassess at each visit.

Psychiatric Adverse Events

Stimulants can exacerbate anxiety, trigger mania in undiagnosed bipolar disorder, and rarely precipitate psychosis in susceptible individuals. A large pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) found that lisdexamfetamine had a proportional reporting ratio of 3.1 for psychosis/mania events compared to all other drugs in the database across all ages [13]. Adolescents with first-degree family history of bipolar disorder should be screened carefully before stimulant initiation.

Dosing and Titration Summary for Adolescents (On-Label ADHD and Off-Label Applications)

| Indication | Starting Dose | Titration | Typical Target | Maximum | |---|---|---|---|---| | ADHD (on-label) | 20 to 30 mg/day | 10 to 20 mg/week | 40 to 60 mg/day | 70 mg/day | | BED (off-label) | 20 to 30 mg/day | 20 mg q1 to 2 weeks | 50 mg/day | 70 mg/day | | Depression augmentation (off-label) | 10 to 20 mg/day | 10 mg q2 weeks | 20 to 40 mg/day | 50 mg/day | | SCT / fatigue (off-label) | 20 mg/day | 10 to 20 mg/week | 40 mg/day | 60 mg/day |

All doses taken orally once daily in the morning. The capsule may be opened and dissolved in water if swallowing is difficult. Do not substitute a different lisdexamfetamine formulation without recalculating the dose.

Informed Consent and the Off-Label Conversation With Adolescents and Families

Prescribing off-label in a Schedule II drug to a minor requires explicit, documented informed consent from a parent or legal guardian and, where developmentally appropriate, assent from the adolescent. The conversation should include:

1. The specific indication being treated and the evidence base (or lack thereof).
2. The fact that FDA approval exists only for ADHD in this age group.
3. Known risks including cardiovascular effects, growth, psychiatric adverse events, and diversion potential.
4. Monitoring plan and expected follow-up intervals.
5. What "stopping criteria" look like: lack of response at adequate dose after 6 to 8 weeks, or emergence of adverse effects.

The American Society of Adolescent Psychiatry does not publish a specific lisdexamfetamine off-label guideline, but the principles align with the APA's 2022 Practice Guideline for the Pharmacological Treatment of Patients with ADHD, which states: "When prescribing off-label, clinicians should document the clinical rationale, evidence reviewed, and the consent process" [14].

Interactions With Other Medications Commonly Used in Adolescents

Adolescents with depression, anxiety, or eating disorders are often on multiple agents. Key interactions to know:

• SSRIs and SNRIs: Serotonergic agents combined with amphetamines carry a theoretical serotonin syndrome risk, though documented cases are rare. Monitor for tremor, hyperthermia, and agitation.
• Bupropion: Bupropion inhibits CYP2D6, which is involved in amphetamine metabolism. Co-administration may raise amphetamine plasma levels. Start at a lower lisdexamfetamine dose when adding to established bupropion.
• MAOIs: Contraindicated. Allow a minimum 14-day washout after stopping any MAOI before starting lisdexamfetamine [FDA label].
• Antacids and urinary alkalinizing agents: These reduce renal amphetamine excretion and may prolong and intensify drug effect. Avoid concurrent use of high-dose antacids.
• Alpha-2 agonists (guanfacine, clonidine): Sometimes co-prescribed for ADHD. The combination is generally well tolerated, but blood pressure monitoring is warranted given opposing cardiovascular mechanisms.

What Happens When Adolescents Transition to Adult Care

One often-overlooked issue: adolescents treated off-label for BED or depression augmentation with Vyvanse will eventually enter adult care. The BED indication becomes on-label at age 18. Clinicians in adult practice receiving these patients should document the prior treatment course, reassess the indication with adult diagnostic criteria, and, where indicated, transition to a formal evidence-based BED treatment protocol. Cognitive behavioral therapy for BED has the strongest long-term evidence across all age groups and should be maintained or initiated if not already in place [15].